Prevalence and management of antibiotic associated diarrhea in general hospitals

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Elseviers, Monique M ^a   Van Camp, Yoleen ^a   Nayaert, Sander ^a   Duré, Khyra ^a   Annemans, Lieven ^b   Tanghe, Ann ^c   Vermeersch, Sebastian ^c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c HICT   (Belgium)

Author keywords

AAD prevalence; AAD related nursing care; AB use point prevalence; Antibiotic associated diarrhea (AAD); Antibiotic use (AB); Clostridium difficile infection; Contamination control

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIPARASITIC AGENT; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC ASSOCIATED DIARRHEA; ARTICLE; BELGIUM; CLINICAL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FEMALE; GENERAL HOSPITAL; HEALTH ECONOMICS; HOSPITAL PATIENT; HUMAN; INTERNAL MEDICINE; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NURSING CARE; OBSERVATIONAL STUDY; PATIENT CARE; PREVALENCE; REHYDRATION; RISK FACTOR; SCREENING; SYMPTOMATOLOGY; VERY ELDERLY; CLOSTRIDIUM INFECTIONS; DIARRHEA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FEMALE; HOSPITALS, GENERAL; HUMANS; MALE; MIDDLE AGED; PENICILLINS; PREVALENCE; YOUNG ADULT;

EID: 84928042675     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0869-0     Document Type: Article

References (17)

1. Esac-3 HCSG. Report on point prevalence survey of antimicrobial prescription in European hospitals, 2009. Belgium: University of Antwerp; 2009.
2. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563-78.
3. Thielman NM, Wilson KH. Antibiotic-associated colitis. In: Mandell GL, Bennett JE, Doolin R, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2005. p. 1249-63.
4. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346-53.
5. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497-504.
6. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-69.
7. Sanford JP, Chambers HF, Eliopoulos GM, Moellering RC, Saag MS. The Sanford guide to antimicrobial therapy. 22nd edition of the Belgium/Luxembourg version 2010-2011. Sperryville USA: Antimicrobial Therapy Inc; 2010.
8. Viseur N, Lambert ML. Epidemiologie van Clostridium difficile infecties in België. Rapport 2012. Brussels, Belgium: Wetenschappelijk Instituut Volksgezondheid; 2012. ISSN: 2034-4627.
9. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol. 2006;44(8):2785-91.
10. Bauer MP, van Dissel JT. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents. 2009;33 Suppl 1:S51-6.
11. IBM SPSS statistics base 20. Chicago, IL: SPSS Inc; 2011
12. Society BIC. Surveillance van Clostridium difficile infecties. Belgium: Wetenschappelijk Instituut Volksgezondheid; 2010.
13. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29(9):823-8.
14. Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect. 2008;70(1):15-20.
15. Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis. 2012;16(11):E786-92.
16. Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2005;22(5):365-72.
17. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-22.